Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck
- PMID: 17303904
- DOI: 10.1385/MO:23:4:463
Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck
Abstract
Objective: The identification of a reliable circulating tumor marker in squamous cell carcinoma of the head and neck (SCCHN) could assist in diagnosis and monitoring response to therapy.
Aim: The aim of this study was to investigate the effectiveness of the serum tumor markers CYFRA 21-1, TPA-M, SCCA, and CEA.
Study design: Serum levels of CYFRA 21-1, TPA-M, SCCA, and CEA were measured in 136 patients with a histologically proven SCCHN before and after treatment and in 125 healthy subjects, as controls. We evaluated the sensitivity and specificity of these tumor markers and to correlate their levels with tumor staging, grading, or performance status.
Results: The study showed that none of the above markers presented satisfactory specificity and sensitivity in early diagnosis. In comparison with the other markers, TPA-M was the most effective of all markers and indicated a positive correlation with the grade of differentiation and nodal status. A remarkable correlation between high levels of TPA-M and CYFRA 21-1 in advanced stages (III, IV) of cancer has been shown.
Conclusions: All the tumor markers that were studied have significant limitations in the early diagnosis of cancer, but TPA-M and CYFRA 21-1 may have a role in monitoring the success of therapy and follow up of patients with SCCHN.
Similar articles
-
Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx.Anticancer Res. 2006 May-Jun;26(3B):2493-7. Anticancer Res. 2006. PMID: 16821638
-
The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.Anticancer Res. 2015 Oct;35(10):5519-24. Anticancer Res. 2015. PMID: 26408719
-
CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.Anticancer Res. 1996 Sep-Oct;16(5B):3117-24. Anticancer Res. 1996. PMID: 8920778
-
Circulating markers in squamous cell carcinoma of the head and neck: a review.Eur J Cancer B Oral Oncol. 1994 Jan;30B(1):23-8. doi: 10.1016/0964-1955(94)90046-9. Eur J Cancer B Oral Oncol. 1994. PMID: 9135969 Review.
-
[Biomarkers for neoplasmas in digestive organs].Gan To Kagaku Ryoho. 2004 Jul;31(7):1015-20. Gan To Kagaku Ryoho. 2004. PMID: 15272578 Review. Japanese.
Cited by
-
Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.Cancer Med. 2021 Feb;10(4):1335-1346. doi: 10.1002/cam4.3737. Epub 2021 Feb 9. Cancer Med. 2021. PMID: 33565282 Free PMC article.
-
Salivary Scca1, Scca2 and Trop2 in Oral Cancer Patients-A Cross-Sectional Pilot Study.Dent J (Basel). 2022 Apr 15;10(4):70. doi: 10.3390/dj10040070. Dent J (Basel). 2022. PMID: 35448064 Free PMC article.
-
Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.PLoS One. 2019 May 9;14(5):e0216561. doi: 10.1371/journal.pone.0216561. eCollection 2019. PLoS One. 2019. PMID: 31071161 Free PMC article.
-
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17. Int J Clin Oncol. 2024. PMID: 38493447
-
Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.Int J Mol Sci. 2018 Mar 24;19(4):971. doi: 10.3390/ijms19040971. Int J Mol Sci. 2018. PMID: 29587347 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials